Vor Biopharma (VOR) Competitors $2.07 0.00 (0.00%) As of 08/8/2025 03:58 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsSEC FilingsShort InterestTrendsBuy This Stock VOR vs. PHVS, SYRE, GPCR, ARDX, VERV, AMPH, AKBA, RCUS, AVXL, and COLLShould you be buying Vor Biopharma stock or one of its competitors? The main competitors of Vor Biopharma include Pharvaris (PHVS), Spyre Therapeutics (SYRE), Structure Therapeutics (GPCR), Ardelyx (ARDX), Verve Therapeutics (VERV), Amphastar Pharmaceuticals (AMPH), Akebia Therapeutics (AKBA), Arcus Biosciences (RCUS), Anavex Life Sciences (AVXL), and Collegium Pharmaceutical (COLL). These companies are all part of the "pharmaceutical products" industry. Vor Biopharma vs. Its Competitors Pharvaris Spyre Therapeutics Structure Therapeutics Ardelyx Verve Therapeutics Amphastar Pharmaceuticals Akebia Therapeutics Arcus Biosciences Anavex Life Sciences Collegium Pharmaceutical Vor Biopharma (NASDAQ:VOR) and Pharvaris (NASDAQ:PHVS) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment. Do analysts recommend VOR or PHVS? Pharvaris has a consensus target price of $36.20, suggesting a potential upside of 79.92%. Given Pharvaris' higher possible upside, analysts plainly believe Pharvaris is more favorable than Vor Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vor Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00Pharvaris 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of VOR or PHVS? 97.3% of Vor Biopharma shares are owned by institutional investors. 2.9% of Vor Biopharma shares are owned by company insiders. Comparatively, 11.8% of Pharvaris shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media prefer VOR or PHVS? In the previous week, Pharvaris had 3 more articles in the media than Vor Biopharma. MarketBeat recorded 3 mentions for Pharvaris and 0 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.98 beat Pharvaris' score of 0.60 indicating that Vor Biopharma is being referred to more favorably in the media. Company Overall Sentiment Vor Biopharma Positive Pharvaris Positive Is VOR or PHVS more profitable? Vor Biopharma's return on equity of 0.00% beat Pharvaris' return on equity.Company Net Margins Return on Equity Return on Assets Vor BiopharmaN/A N/A N/A Pharvaris N/A -54.02%-50.36% Which has more volatility & risk, VOR or PHVS? Vor Biopharma has a beta of 2.06, indicating that its share price is 106% more volatile than the S&P 500. Comparatively, Pharvaris has a beta of -2.81, indicating that its share price is 381% less volatile than the S&P 500. Which has better valuation and earnings, VOR or PHVS? Pharvaris is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVor BiopharmaN/AN/AN/A-$1.51-1.37PharvarisN/AN/A-$145.24M-$3.01-6.68 SummaryVor Biopharma beats Pharvaris on 9 of the 13 factors compared between the two stocks. Get Vor Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VOR vs. The Competition Export to ExcelMetricVor BiopharmaBiological Products, Except Diagnostic Substances IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$262.14M$213.09M$2.56B$9.71BDividend YieldN/AN/A2.56%4.12%P/E Ratio-1.37N/A22.2424.80Price / SalesN/AN/A77.25191.12Price / CashN/AN/A23.8958.47Price / BookN/AN/A37.735.60Net IncomeN/AN/A$31.01M$266.27M7 Day Performance-1.43%-9.44%1.56%5.08%1 Month Performance-10.39%-19.80%1.16%0.61%1 Year PerformanceN/A152.44%28.09%22.83% Vor Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VORVor Biopharma0.3885 of 5 stars$2.07flatN/AN/A$262.14MN/A-1.37140Gap UpPHVSPharvaris1.5327 of 5 stars$20.00+0.6%$36.20+81.0%+25.1%$1.04BN/A-6.6430Upcoming EarningsSYRESpyre Therapeutics2.6405 of 5 stars$16.26-4.2%$53.40+228.4%-38.9%$1.02B$890K-4.3173News CoveragePositive NewsEarnings ReportAnalyst ForecastGap DownGPCRStructure Therapeutics1.8541 of 5 stars$17.59-1.2%$76.17+333.0%-51.7%$1.02BN/A-20.22136News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionARDXArdelyx4.3392 of 5 stars$4.33+2.1%$10.88+151.2%-8.6%$1.01B$333.61M-19.6890Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionVERVVerve Therapeutics2.8888 of 5 stars$11.13flat$14.57+30.9%N/A$992.13M$32.33M-5.27110Upcoming EarningsAMPHAmphastar Pharmaceuticals4.3082 of 5 stars$21.21+1.2%$32.33+52.4%-44.4%$987.56M$731.97M7.682,028Trending NewsAnalyst ForecastAKBAAkebia Therapeutics3.9541 of 5 stars$3.72+1.1%$6.75+81.5%+208.1%$967.81M$160.18M-17.71430News CoverageRCUSArcus Biosciences2.1689 of 5 stars$9.16+0.3%$21.29+132.4%-41.7%$966.73M$258M-2.19500News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionAVXLAnavex Life Sciences3.5507 of 5 stars$11.20-0.9%$44.00+292.9%+75.7%$965.21MN/A-20.3640Upcoming EarningsCOLLCollegium Pharmaceutical3.5663 of 5 stars$30.07+0.7%$43.75+45.5%-1.6%$959.46M$631.45M24.65210Trending NewsAnalyst Upgrade Related Companies and Tools Related Companies PHVS Competitors SYRE Competitors GPCR Competitors ARDX Competitors VERV Competitors AMPH Competitors AKBA Competitors RCUS Competitors AVXL Competitors COLL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VOR) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vor Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vor Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
